TROP2- and CDH6-Directed ADCs in Gynecologic Cancers — An Interview with Dr Ramez Eskander on Key Presentations from the Society of Gynecologic Oncology 2026 Annual Meeting

Featuring an interview with Dr Ramez Eskander, including the following topics:Overview of antibody-drug conjugates (ADCs) and their role in the management of gynecologic cancers; considerations in sequencing (0:00)Choosing between FRɑ- and HER2-directed ADCs for dually eligible patients; role of antigenic target in predicting efficacy benefit of ADCs (7:53)Comparative efficacy and safety of ADCs and conventional chemotherapy (12:58)Current and investigational targets of ADCs in gynecologic cancers (17:14)Current research surrounding raludotatug deruxtecan (R-DXd) and its potential role in clinical practice (21:56)Safety and tolerability profiles of ADCs, including R-DXd, and potential mitigation strategies (27:36)Overview of available TROP2-directed ADCs for gynecologic cancers, including key clinical data (33:34)Evolving use of TROP2-directed ADCs for gynecologic cancers in clinical trials (39:05)Oral mucositis/stomatitis associated with TROP2-directed ADCs and potential mitigation strategies (44:38)CME information and select publications